Product
UCART19
1 clinical trial
1 indication
Indication
Advanced Lymphoid LeukemiaClinical trial
Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)Status: Active (not recruiting), Estimated PCD: 2025-02-01